TN2011000134A1 - Polytherapie destinee a traiter une infection par le vhc - Google Patents
Polytherapie destinee a traiter une infection par le vhcInfo
- Publication number
- TN2011000134A1 TN2011000134A1 TN2011000134A TN2011000134A TN2011000134A1 TN 2011000134 A1 TN2011000134 A1 TN 2011000134A1 TN 2011000134 A TN2011000134 A TN 2011000134A TN 2011000134 A TN2011000134 A TN 2011000134A TN 2011000134 A1 TN2011000134 A1 TN 2011000134A1
- Authority
- TN
- Tunisia
- Prior art keywords
- polytherapie
- destinee
- vhc
- une infection
- infection par
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 102000012479 Serine Proteases Human genes 0.000 abstract 1
- 108010022999 Serine Proteases Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229950000038 interferon alfa Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2009/056771 WO2010033443A1 (en) | 2008-09-17 | 2009-09-14 | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2011000134A1 true TN2011000134A1 (en) | 2012-09-05 |
Family
ID=55024422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2011000134A TN2011000134A1 (en) | 2009-09-14 | 2011-03-15 | Polytherapie destinee a traiter une infection par le vhc |
Country Status (1)
| Country | Link |
|---|---|
| TN (1) | TN2011000134A1 (en) |
-
2011
- 2011-03-15 TN TN2011000134A patent/TN2011000134A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY152824A (en) | Combination of hcv ns3 protease inhibitor with interferon and ribavirin. | |
| PH12012500827A1 (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| MX2009009174A (en) | Inhibitors of serine proteases for the treatment of hcv infections. | |
| NZ599284A (en) | Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor | |
| MX2009009176A (en) | Inhibitors of serine proteases. | |
| MY148123A (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| ES2572329A2 (en) | Combination of at least two antiviral agents of direct action and ribavirina but not interfered, for use in the vhc treatment (Machine-translation by Google Translate, not legally binding) | |
| JO2593B1 (en) | HCV NS3 Protease Inhibitors | |
| TW200510391A (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| WO2007016476A3 (en) | Hepatitis c serine protease inhibitors and uses therefor | |
| MY164469A (en) | Hcv ns3 protease inhibitors | |
| MX2010006210A (en) | Fluorinated tripeptide hcv serine protease inhibitors. | |
| SG159385A1 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease | |
| WO2005077969A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| TNSN06071A1 (en) | Use of modified cyclosporins for the treatment of hcv disorders | |
| EA200900969A1 (en) | MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE | |
| PH12013500559A1 (en) | Combination therapy for treating hcv infection | |
| MX2010008108A (en) | Heteroaryl-containing tripeptide hcv serine protease inhibitors. | |
| WO2009067225A3 (en) | Boceprevir derivatives for the treatment of hcv infections | |
| PH12013500558A1 (en) | Solid state forms of a potent hcv inhibitor | |
| TN2011000134A1 (en) | Polytherapie destinee a traiter une infection par le vhc | |
| UA90909C2 (en) | Hcv ns3 protease inhibitors | |
| TH139548A (en) | Combination therapy For the treatment of HCV infection | |
| TN2013000134A1 (en) | Combination therapy for treating hcv infection | |
| PH12015502258B1 (en) | Solid oral dosage formulation of hcv inhibitor in the amorphous state |